Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990017 | 0.87 | MAPT (0.58) | HCAR3MAPTMAPK1POLBABCB1 | |
| SCHEMBL29729424 | 0.87 | MAPT (0.58) | HCAR3MAPTMAPK1POLBABCB1 | |
| SCHEMBL16721694 | 0.83 | HCAR3 (0.54) | HCAR3MAPTMAPK1ABCB1ABCC1 | |
| SCHEMBL16721691 | 0.83 | HCAR3 (0.54) | HCAR3MAPTMAPK1ABCB1ABCC1 | |
| SCHEMBL14764647 | 0.83 | ALDH1A1 (0.67) | HCAR3MAPTMAPK1ABCB1ABCC1 | |
| SCHEMBL7352966 | 0.82 | HCAR3 (0.47) | HCAR3MAPTMAPK1ABCB1ABCC1 | |
| SCHEMBL10249208 | 0.81 | HCAR3 (0.63) | HCAR3MAPTPOLBRAB9ACYP1A2 | |
| SCHEMBL10089736 | 0.81 | CRHBP (0.68) | HCAR3MAPTMAPK1POLBCYP1A2 | |
| SCHEMBL339294 | 0.81 | HCAR3 (0.58) | HCAR3MAPTMAPK1ABCB1ABCC1 | |
| SCHEMBL7369772 | 0.80 | HCAR3 (0.61) | HCAR3MAPTMAPK1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| CN-114585360-B | Methods of using the same for treating epilepsy | 特维娜有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4200292-B1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-13 | — | — | EP | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-9125901-B2 | 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| CN-104219954-A | Benzamide derivatives | TRANSLATIONAL GENOMICS RES INST | 2014-12-17 | — | — | CN | disclosed |
| EP-2445345-B1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL GENOMICS RES INST (US) | 2014-08-27 | — | — | EP | disclosed |
| CN-103298788-A | Pyridine derivative and medicinal agent | NIPPON SHINYAKU CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-8314131-B2 | Triazole fused heteroaryl compounds and methods of use thereof | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120142922-A1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2445345-A1 | BENZAMIDE DERIVATIVES | The Translational Genomics Research Institute (US) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010151441-A1 | BENZAMIDE DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100292234-A1 | TRIAZOLE FUSED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | HCAR3 291/4885MAPT 3799/4885MAPK1 1168/4885 |
| US-20100292234-A1 | TRIAZOLE FUSED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | MAPK1, MAPK3, CNKSR1 | HCAR3 128/4885MAPT 1469/4885MAPK1 1/4885 |
| US-20230295122-A1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | HCAR3 2625/4885MAPT 4616/4885MAPK1 263/4885 |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR7 | HCAR3 2625/4885MAPT 4616/4885MAPK1 263/4885 |
| US-20120142922-A1 | BENZAMIDE DERIVATIVES | BRDT, BRD3, BRD2 | HCAR3 3437/4885MAPT 4124/4885MAPK1 4506/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | HCAR3 291/4885MAPT 3799/4885MAPK1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.